Slide 1: Second Quarter 2024 Earnings
Click Here to Edit Title Second Quarter 2024 Earnings August 1, 2024
Slide 2: Cautionary Statement; Non-GAAP Measures
Cautionary Click Here to Statement Edit Title Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements ma
Slide 3: IDEX Overview
Click Here IDEX Overview to Edit Title Second Quarter Results • Solid performance despite headwinds from uncertainty • Industrial softness driven by project delays • No launch yet in Semicon or Life Sciences & Analytical Instrumentation • Impressive Dispensing growth in emerging markets Looking Ahea
Slide 4: Innovation for Growth
Innovation Click Here for to Edit Growth Title Health & Science Fluid & Metering Fire & Safety / Technologies Technologies Diversified Products MP350 Microlyser™ Melles Griot® XPLAN™ Trebor QNXT heater WildCAT all-in-one control Verisighht Ultra Processor CCG Lens Series systems solution 4
Slide 5: Disciplined Capital Deployment
Disciplined Click Here to Capital Edit Title Deployment Acquisitions Expands Applied Material Science Technologies Portfolio Divestiture Analytic Solution addition to Intelligent Water Platform SewerScout™ VScout™ Terralytics™ Tuning our portfolio for profitable growth 5 5
Slide 6: Q2 2024 Financial Performance
Q2 Click 2024 Here Financial to Edit Title Performance ($ in millions excl. EPS) Sales Adj. EBITDA Margin* Adj. EPS* Free Cash Flow* -4% Organic* -60 bps -6% -2% $846 28.4% 27.8% $807 $2.18 $120 $2.06 $118 Q2'23 Q2'24 Q2'23 Q2'24 Q2'23 Q2'24 Q2'23 Q2'24 Organic* FX M&A YoY∆ Sales Growth -4% -1% - -5
Slide 7: Q2 2024 Adjusted EBITDA Walk
Q2 Click 2024 Here Adjusted to Edit Title EBITDA Walk ($ in millions) 2Q ‘23 Act Volume Flow Price / Mix Acq / Div / FX 2Q ‘24 Act Adj. EBITDA* Through Productivity / Adj. EBITDA* Inflation Flow through Organic flow Total flow at PY GM%* through** through*** 44.7% (48.7%) (42.4%) **Excludes Acquisit
Slide 8: Q2 2024: Fluid & Metering Technologies
Q2 Click 2024: HereFluid to Edit & Metering Title Technologies ($ in millions) Orders Sales Adj. EBITDA Margin* Highlights -4% Organic* Flat Organic* -140 bps • Municipal Water strength • Energy market remains stable $325 $319 35.1% 33.7% $303 • Ag cyclically down $287 • Lower volume leverage and hi
Slide 9: Q2 2024: Health & Science Technologies
Q2 Click 2024: HereHealth to Edit&Title Science Technologies ($ in millions) Orders Sales Adj. EBITDA Margin* Highlights +5% Organic* -11% Organic* +10 bps • Life Science & Analytical Instrumentation in line with 27.6% 27.7% expectations $285 $299 $340 • Semiconductor lagging $304 • Industrials proj
Slide 10: Q2 2024: Fire & Safety / Diversified Products
Q2 Click 2024: HereFire to Edit & Safety Title / Diversified Products ($ in millions) Orders Sales Adj. EBITDA Margin* Highlights +6% Organic* +1% Organic* -40 bps • Strong Dispensing Emerging Markets • Fire NA OEM production ramp $189 $185 $185 $179 29.4% 29.0% • BAND-IT auto and industrial softnes
Slide 11: 2024 Guidance Summary
2024 Click Here Guidance to Edit Summary Title Third Quarter Full Year Full Year Current Guidance Current Guidance Prior Guidance Revenue % vs Prior Year Organic* 0% – 1% (2%) - (1%) 0% - 2% growth EBITDA % Adjusted* ~27% ~27% ~28% Earnings Per Share Reported* $1.61 - $1.66 $6.85 - $6.95 $7.13 - $7.
Slide 12: IDEX Value Drivers
IDEXHere Click ValuetoDrivers Edit Title ORGANIC INORGANIC MARGIN GROWTH GROWTH EXPANSION • Leading market entitlement • Strong funnel of M&A opportunities • Leading the IDEX Op Model • Pricing Execution • Fast growing companies • 80/20 • Growth Bets Prioritization • Disciplined capital deployment •
Slide 13: Non-GAAP Reconciliations
Click Here to Edit Title Non-GAAP Reconciliations
Slide 14: Table 1: Reconciliations of Change in Net Sales to Organic Net Sales
Table 1: Reconciliations of the Change in Net Sales to Organic Net Sales FMT HST FSDP IDEX Three Months Ended June 30, 2024 Change in net sales (2%) (11%) —% (5%) Less: Net impact from acquisitions/divestitures(1) (1%) —% —% —% Impact from foreign currency (1%) —% (1%) (1%) Change in organic net sal
Slide 15: Table 3: Reported-to-Adjusted Net Income and Diluted EPS
Table 3: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, other than per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Reported net income attributable to IDEX $ 141.3 $ 138.6 $ 262.7
Slide 16: Table 4: Reconciliations of Net Income to Adjusted EBITDA
Table 4: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Reported net income $ 141.2 $ 138.5 $ 262.5 $ 278.3 Provision for income taxes 38.0 40.0 71.2 80.0 Interest expense - net 8.1 13.3 17.5 26.4 Gain
Slide 17: Table 7: Reconciliation of Estimated 2024 Diluted EPS to Adjusted EPS
Table 7: Reconciliation of Estimated 2024 Diluted EPS Attributable to IDEX to Adjusted Diluted EPS Attributable to IDEX Guidance Third Quarter 2024 Full Year 2024 Estimated diluted EPS attributable to IDEX $1.61 - $1.66 $6.85 - $6.95 Fair value inventory step-up charge — 0.03 Tax impact on fair valu